In a clinical trial, anti-CD19 CAR T cells from EBV-specific T cells were administered to pediatric ALL patients with vaccination using EBV-transformed lymphoblastoid cell lines. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.